We summarize results from the phase II TIDAL trial assessing the safety and efficacy of intermittent dosing of zandelisib in patients with R/R follicular lymphoma.
Momelotinib improved OS vs best available therapy in patients with ruxolitinib-experienced myelofibrosis, according to data from a MAIC analysis.
Annals of Surgical Oncology – While solid pseudopapillary tumor (SPT) of the pancreas are oncologically low-risk tumors, their resection with pancreaticoduodenectomy (PD) or partial pancreatectomy…
Lee et al. show that neutrophil extracellular traps (NETs) establish the pre-metastatic niche in the omentum by recruiting innate-like B cells and eliciting IL-10 production in…
Explore the 2024 CPT codes for oncology patient navigation and how pharma can support improved patient outcomes.
Oncology Times reports essential clinical news for oncologists, hematologists and other cancer care
Retrospective data showed there was no OS difference between 3 frontline CDK4/6 inhibitor combos in HR-positive breast cancer.
Pancreatic cancer is a tough disease to catch early because it doesn’t always cause clear symptoms right away. Still, noticing changes in your body can…
During an in-person Community Case Forum event in Miami, Florida, Mike Cusnir, MD, discussed the ARANOTE study outcomes presented at ESMO 2024 and how they…
Stacey A. Cohen, MD, discusses insights into the evolving role of circulating tumor DNA in clinical decision-making for patients with colorectal cancer.
The FDA accepted and granted priority review to an NDA for avutometinib plus defactinib in recurrent KRAS-mutated low-grade serous ovarian cancer.
